



The TIMI Trials

TIMI 31

OBJECTIVE: To evaluate the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST-elevation myocardial infarction.

1. Gibson CM, Zorkun C, Molhoek P, Zmudka K, Greenberg M, Mueller H, Wesdorp J, Louwerenburg H, Niederman A, Westenburg J, Bikkina M, Batty J, de Winter J, Murphy SA, McCabe CH. Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: Results of the TIMI 31 trial. *J Thromb Thrombolysis* 2006;22:13-21.